Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Oct 27;6(33):34047-8.
doi: 10.18632/oncotarget.6026.

Targeting lymphatics in inflammatory bowel disease

Silvia D'Alessio  1 , Carlotta Tacconi  1 , Silvio Danese  1
Affiliations
Editorial

Targeting lymphatics in inflammatory bowel disease

Silvia D'Alessio et al. Oncotarget. .
No abstract available

Keywords: IBD; VEGFC; lymphatic function; macrophages.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Potential use of lymphangiogenic factors (VEGF-C) as a novel therapeutic approach for the treatment of IBD
IBD tissues show lymphatic dysfunction, which leads to accumulation of fluids, inflammatory cells and reduced bacterial antigen clearance (left panel). VEGF-C treatment induces lymph drainage and inflammatory cell migration towards draining lymphnodes (MLN), along with activation of macrophages (MΦ) and bacterial antigen clearance (right panel), in a STAT6-dependent manner. Dotted black arrow: lymph drainage.
See this image and copyright information in PMC

References

    1. Rahier JF, et al. Inftamm Bowel Dis. 2013;19(10):2084–90. - PubMed
    1. Heinsbroek SE, et al. Expert Rev Mol Med. 2009;11:el4. - PubMed
    1. Weisser SB, et al. J Leukoc Biol. 2011;90:483–92. - PubMed
    1. Jurisic G, et al. Inftamm Bowel Dis. 2012;19:1983–9. - PMC - PubMed
    1. Skobe M, et al. Am J Pathol. 2001;159:893–903. - PMC - PubMed

Publication types

MeSH terms

Substances